Clinical Trial Update: Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating a voriconazole and anidulafungin combination for invasive aspergillosis in pediatric subjects has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Aspergillosis
• Invasive Pulmonary Aspergillosis
• Neuroaspergillosis

Drugs mentioned

• Eraxis (Anidulafungin) (Anidulafungin)
• Vfend (voriconazole) (voriconazole)

Snippet

Sponsor: Pfizer | Conditions: Aspergillosis, Invasive Pulmonary Aspergillosis | Phase 3 | Status: WITHDRAWN